Favorable role of IDH 1/2 mutations aided with MGMT promoter gene methylation in the outcome of patients with malignant glioma

The implications of molecular biomarkers 1/2 mutations and gene promoter methylation were evaluated for prognostic outcome of glioma patients. Glioma cases were analyzed for 1/2 mutations and promoter methylation by DNA sequencing and methylation-specific PCR, respectively. Mutations found in 1/2 genes totaled 63.4% (N = 40) wherein 1 mutations were significantly associated with oligidendrioglioma (p = 0.005) and astrocytoma (p = 0.0002). 1 mutants presented more, 60.5% in promoter-methylated cases (p = 0.03). 1 mutant cases had better survival for glioblastoma and oligodendrioglioma (log-rank p = 0.01). Multivariate analysis confirmed better survival in methylation carriers (hazard ratio [HR]: 0.59; p = 0.031). Combination of both biomarkers showed better prognosis on temozolomide (p